South African tycoon Stephen Saad’s Aspen stake loses $18 million
Stephen Saad’s Aspen stake drops $18 million as shares fall 5.45% in 16 days, deepening losses for South Africa’s largest drugmaker.
Stephen Saad
Aspen’s market slide wipes $20 million off Stephen Saad’s stake
Stephen Saad’s Aspen Pharmacare stake drops by $20 million as the company’s stock slips 6 percent on the Johannesburg Stock Exchange (JSE).
South African pharma tycoon Stephen Saad’s Aspen stake tops $340 million
Aspen Pharmacare shares edge higher, boosting CEO Stephen Saad’s holdings above $340 million despite the stock’s 37% year-to-date decline.
South Africa’s Stephen Saad expects $50 million sales from Aspen’s weight loss drug
South African pharma tycoon Stephen Saad says Aspen’s weight loss drug could reach $50 million in sales within two years.
South African tycoon Stephen Saad’s Aspen Pharmacare swings to $61.4 million loss in 2025
Aspen Pharmacare reports $61.34 million loss as revenue falls 3 percent, driven by restructuring and manufacturing challenges.
South African pharma tycoon Stephen Saad loses $44 million from Aspen stake
Aspen Pharmacare shares slide 33 percent, cutting Stephen Saad’s stake by $44 million amid global pharma pressures.
South African pharma mogul Stephen Saad’s Aspen stake sinks under $360 million
Aspen Pharmacare CEO Stephen Saad loses $32 million in 13 days as stock slumps; his stake now worth under $360 million amid JSE sell-off.
South African pharma tycoon Stephen Saad’s Aspen stake falls below $400 million
Stephen Saad’s stake slips below $400 million as Aspen shares fall 5.2% dragging market cap under $3 billion.
South African tycoon Stephen Saad's Aspen opens regional headquarters in Saudi Arabia
Aspen’s investment comes amid a broader push to localize manufacturing, enhance drug supply chains, and develop regional talent.
Stephen Saad’s Aspen stake drops $21 million in value
This mirrors wider investor caution amid challenges facing the global pharmaceutical sector and instability in emerging markets.
Stephen Saad raises Aspen stake by $5.6 million amid stock slump
Stephen Saad invests $5.6 million more in Aspen amid its biggest stock slump in two decades, signaling confidence in the company’s long-term outlook.
Stephen Saad loses $130 million as Aspen shares fall amid contract dispute
This follows a $148.7 million contract dispute tied to mRNA technology.
Stephen Saad’s Aspen faces $148.7 million contract dispute
Aspen shares dive 30% amid $148.7 million mRNA tech dispute, stoking investor fears over financial stability.
Stephen Saad’s stake in Aspen slips below $450 million
South African pharma tycoon Stephen Saad’s stake in Aspen Pharmacare drops to $434.35 million, losing $62.85 million in 15 days.
Stephen Saad’s wealth takes a hit as Aspen Pharmacare stock plunges, erasing $41 million
This downturn follows a $44 million gain in January, which had lifted his stake to R10.26 billion ($550.1 million).
Stephen Saad leads Africa’s largest drugmaker to $1.2 billion in half-year revenue
The growth was fueled by the successful integration of acquired products in Latin America.